DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...
BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.
DexCom, Inc. (NASDAQ:DXCM) Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, expectations were $0.57. Operator: Ladies and gentlemen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results